Sponsored Links
| All-Oral Combination Study With PSI-7977 For HCV Genotypes 1, 2 And 3 Initiated |
 |
 |
 |
| Medical News - Liver Disease and Hepatitis | |||
|
Pharmasset, Inc. (Nasdaq: VRUS) announced the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's (NYSE: BMY) NS5A replication complex inhibitor, for the treatment of chronic hepatitis C (HCV)... Read more: Liver Disease / Hepatitis News From Medical News Today
|